
This Week in Managed Care: January 16, 2016
This week in managed care the top stories included the announcement of a initiative to cure cancer, pharmaceutical company executives brushed off public outrage over drug prices, and the president's nominee for FDA commissioner has passed his first hurdle.
Hello, I’m Sara Belanger, with The American Journal of Managed Care. Welcome to This Week in Managed Care, from the Managed Markets News Network.
"Moonshot" Initiative for Cancer
With one year left in office, President Obama this week tapped Vice President Joe Biden to lead an all-out effort to cure cancer.
The so-called “Moonshot” initiative will combine new funding with government support to promote cooperation between public and private sectors for things like data sharing. In a blog post, the vice president wrote that important discoveries are being made, “but the science, data and research are trapped in silos, preventing faster progress and greater reach to patients.”
Biden and his staff are meeting with leading scientists, both in the US and abroad. They will travel next week to meet with scientists who are gathering in Davos, Switzerland, at the World Economic Forum.
For more on this effort,
ACA Changes in the States
Changes in State Houses mean that Medicaid expansion and exchanges are moving in different directions.
In Louisiana, John Bel Edwards was sworn in as the state’s new governor on Monday, and
Louisiana is one of the poorest states in the country and has high rates of cancer, diabetes, and obesity, and Edwards promised to expand Medicaid as soon as possible when he campaigned last fall.
But Kentucky, which received national attention for reducing its uninsured rate by more than 11%, is
Bevin also wants to change Kentucky’s Medicaid program to require cost-sharing for people above 100% of the poverty level.
Rising Drug Prices
Rising prescription drug prices received plenty of attention this week. Congressional Democrats sent a letter to the National Institutes of Health asking for an investigation and
In San Francisco, protesters faced off with pharmaceutical representatives at the JP Morgan Healthcare conference, but executives
Most of the outrage was directed at Gilead Sciences over the price of the hepatitis C drug, Sovaldi. The therapy came on the market at $84,000 a year but has since faced competition. Last month, a Senate investigation found that Gilead knew its price would put Sovaldi off limits for many patients who needed it.
Senate Panel Confirms Califf Nomination
A Senate panel this week
Sanders is concerned about Califf’s ties to the pharmaceutical industry, while Senator Lisa Murkowski of Alaska wants assurances about pending FDA rules that would harmful to her state’s salmon industry.
ACO Coalition Spring Meeting
Registration is under way for the spring meeting of the ACO and Emerging Healthcare Delivery Coalition, which is traveling to Scottsdale, Arizona, on April 28th and 29th. For more information,
For all of us at the Managed Markets News Network, I’m Sara Belanger. Thanks for joining us.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.